Ranjana H Advani
Affiliation: Stanford University
- Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporineRanjana Advani
Stanford University Medical Center, Stanford, CA 94305 5821, USA
Leuk Lymphoma 48:521-5. 2007..By interrupting T-cell activation, CsA may alter the immune dysregulation that characterizes AILT. The efficacy of CsA is being explored in patients with recurrent AILT in a prospective trial (ECOG 2402)...
- Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP)Dita Gratzinger
Department of Pathology, Stanford University School of Medicine, CA 94305 5324, USA
Br J Haematol 148:235-44. 2010..In contrast to our prior results with chemotherapy alone, microvessel density was not prognostic of PFS or OS with R-CHOP-like therapy...
- Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaRanjana H Advani
Stanford University Medical Center, Stanford, California
Clin Cancer Res . 2016....
- Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 TrialRanjana H Advani
Ranjana H Advani, Richard T Hoppe, and Sandra J Horning, Stanford University, Stanford Joseph M Tuscano, University of California, Davis Cancer Center, Sacramento, CA Fangxin Hong, Dana Farber Cancer Institute, Boston, MA Richard I Fisher and Jonathan W Friedberg, University of Rochester, Rochester, NY Nancy L Bartlett, Washington University School of Medicine, St Louis, MO K Sue Robinson, Queen Elizabeth II Health Science Center, Halifax, Nova Scotia Randy D Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia Douglas A Stewart, Tim Baker Cancer Institute, Calgary, Alberta, Canada Henry Wagner Jr, Penn State Cancer Institute, Hershey, PA Patrick J Stiff, Loyola University Medical Center, Maywood Leo I Gordon, Northwestern University, Chicago, IL Bruce D Cheson, Georgetown University Hospital, Washington, DC Brad S Kahl, University of Wisconsin, Madison, WI Kristie A Blum, Ohio State University, Columbus
J Clin Oncol 33:1936-42. 2015..We report results of a planned subgroup analysis in patients with stage I or II bulky mediastinal Hodgkin lymphoma (HL)...
- A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factorsSven de Vos
David Geffen School of Medicine at UCLA, University of California Los Angeles, 650 Charles E, Young Drive 11 934 Factor Bldg, Los Angeles, CA 90095 1678, USA
J Hematol Oncol 7:44. 2014..Dacetuzumab (SGN-40), a non-blocking, partial agonist, humanized IgG1, anti-CD40 monoclonal antibody, has previously demonstrated anti-lymphoma activity in a phase I study...
- Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignanciesNancy L Bartlett
Washington University Medical School, St Louis, MO, USA
J Hematol Oncol 7:24. 2014..gov NCT00947856)...
- Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trialR H Advani
Departments of Medicine Oncology, Stanford University Medical Center, 875 Blake Wilbur Drive, CC 2338, Stanford, CA 94305, USA
Ann Oncol 24:1044-8. 2013..Stanford V chemotherapy was administered for 8 weeks followed by radiation therapy (RT) 30 Gy to involved fields (IF). Freedom from progression (FFP), disease-specific survival (DSS) and overall survival (OS) were estimated...
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesRanjana H Advani
Stanford University Medical Center, Stanford, CA 94305 5821, USA
J Clin Oncol 31:88-94. 2013..We evaluated ibrutinib (PCI-32765), a small-molecule irreversible inhibitor of BTK, in patients with B-cell malignancies...
- Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's diseaseDiane Tseng
Department of Radiation Oncology, Stanford University School of Medicine, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
Radiat Oncol 7:5. 2012..We hypothesized that quantitative PET parameters may have predictive value beyond that of traditional clinical factors such as the International Prognostic Score (IPS) among Hodgkin's disease (HD) patients...
- Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experienceRanjana H Advani
Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, California 94305, USA
Int J Radiat Oncol Biol Phys 81:1374-9. 2011..We sought to determine the prognostic significance of these factors in patients with early-stage disease treated at Stanford University Medical Center...
- Management of advanced stage Hodgkin lymphomaRanjana Advani
Stanford University Medical Center, Stanford, California 94305, USA
J Natl Compr Canc Netw 4:241-7. 2006....
- Optimal therapy of advanced Hodgkin lymphomaRanjana Advani
Stanford University Medical Center, Stanford, CA 94305, USA
Hematology Am Soc Hematol Educ Program 2011:310-6. 2011..Lastly, the expanding population of survivors cured of HL outnumbers patients with the disease and needs to be monitored for therapy-related late effects...
- Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic inRanjana H Advani
Stanford University, Stanford, CA 94305, USA
Br J Haematol 151:143-51. 2010..The prognostic discrimination provided by the E-IPI for low and low-intermediate elderly DLBCL patients needs validation by other datasets...
- Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedulesRanjana H Advani
Stanford University Medical Center, Stanford, California, USA
Clin Cancer Res 16:2167-75. 2010..We report the phase 1 experience of voreloxin in patients with relapsed/refractory solid tumors, including dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), pharmacokinetics, and clinical activity...
- A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancerRanjana Advani
Oncology Division, Stanford University School of Medicine, Stanford, CA 94305 5151, USA
Invest New Drugs 23:467-77. 2005..A phase I study was performed to determine the maximum tolerated dose (MTD), safety profile and pharmacology of aprinocarsen (ISIS 3521), an antisense oligonucleotide to protein kinase C-alpha, in patients with refractory solid tumors...
- Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphomaRanjana Advani
Division of Oncology, Stanford University Medical Center, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
J Clin Oncol 27:4371-7. 2009..To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics, and antitumor activity of dacetuzumab in patients with refractory or recurrent B-cell non-Hodgkin's lymphoma (NHL)...
- Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapyRanjana Advani
Division of Oncology, Department of Medicine, Stanford University Medical Center, 875 Blake Wilber Drive, Stanford, CA 94305, USA
J Clin Oncol 22:1454-9. 2004....
- Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's diseaseRanjana Advani
Stanford University Comprehensive Cancer Center, Stanford, CA 94305, USA
J Clin Oncol 25:3902-7. 2007..To correlate [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) status after chemotherapy, but before radiation, with outcome in patients treated with the Stanford V regimen...
- A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapyMichael S Binkley
a Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA
Leuk Lymphoma 57:604-8. 2016..Following R-CT and RT or DA-EPOCH-R, 5-year and 3-year FFP and OS were both 100%. Both R-CHOP/R-VACOP-B with RT and DA-EPOCH-R demonstrate excellent outcomes. ..
- Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trialsMichael Zach Koontz
Stanford University Medical Center, 875 Blake Wilbur Dr, CC 2338, Stanford, CA 94305, USA
J Clin Oncol 31:592-8. 2013..To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive generations of Stanford clinical trials...
- Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)Julie E Chang
University of Wisconsin, Madison, WI
Blood 123:1665-73. 2014..This study was registered at www.clinicaltrials.gov as #NCT00433537. ..
- Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialKing L Tan
Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada
Blood 120:3280-7. 2012..We demonstrate the prognostic significance of TAMs in locally extensive and advanced-stage CHL in a multicenter phase 3 randomized controlled clinical trial...
- Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphomaRanjana H Advani
Ranjana H Advani, Sandra J Horning, Richard T Hoppe, Sarah Daadi, John Allen, and Yasodha Natkunam, Stanford University Medical Center, Stanford, CA and Nancy L Bartlett, Washington University School of Medicine, St Louis, MO
J Clin Oncol 32:912-8. 2014..Universal expression of CD20 by malignant cells in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) led us to evaluate rituximab (R) as a therapeutic option...
- Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignanciesPeter S Galatin
Department of Medicine, Oncology, Stanford University School of Medicine, Stanford, CA, USA
Invest New Drugs 29:971-7. 2011..The present study was designed to determine the maximum tolerated dose (MTD) of oblimersen (antisense Bcl-2) and gemcitabine when administered to patients with refractory malignancies...
- Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOPRaquel Malumbres
Department of Medicine, Division of Hematology Oncology and Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami, FL 33136, USA
Blood 111:5509-14. 2008..008). These findings demonstrate that the prognostic value of the 6-gene model remains significant in the era of R-CHOP treatment and that the model can be applied to routine FFPE tissue from initial diagnostic biopsies...
- Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CTRyan C Lynch
From the Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
Am Soc Clin Oncol Educ Book 35:e376-85. 2016..Longer follow-up is required to assess whether this strategy impacts overall survival (OS). Herein, we review the results of recent trials using interim PET-CT-based adaptive design in the treatment of advanced HL. ..
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeMargaretha G M Roemer
Margaretha G M Roemer, Robert A Redd, Heather Homer, Courtney F Connelly, Gordon J Freeman, Philippe Armand, Bjoern Chapuy, Donna S Neuberg, and Margaret A Shipp, Dana Farber Cancer Institute Azra H Ligon, Heather H Sun, and Scott J Rodig, Brigham and Women s Hospital, Boston, MA Margaretha G M Roemer and Daphne de Jong, VU University Medical Center, Amsterdam, the Netherlands and Ranjana H Advani, Yasodha Natkunam, Sarah E Daadi, and Richard T Hoppe, Stanford University Medical Center, Stanford, CA
J Clin Oncol 34:2690-7. 2016..The unique composition of cHL limits its analysis with high-throughput genomic assays. Therefore, the precise incidence, nature, and prognostic significance of PD-L1/PD-L2 alterations in cHL remain undefined...
- Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)Kristen Ganjoo
Stanford University, Stanford, CA, USA
Leuk Lymphoma 55:768-72. 2014..Studies of novel therapeutics are needed for this patient population, whose clinical outcome remains poor...
- Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experienceDaryl Tan
Department of Medicine, Oncology Division, Stanford University, Stanford, CA 94305, USA
Blood 122:981-7. 2013..Several factors, including better supportive care and effective therapies for relapsed disease, are likely responsible for this improvement. ..
- In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 studyYoun H Kim
Department of Dermatology, Stanford University School of Medicine, CA, USA
Blood 119:355-63. 2012..This study is registered at www.clinicaltrials.gov as NCT00226993...
- Current concepts and controversies in the management of early stage Hodgkin lymphomaLauren S Maeda
Department of Medicine Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
Leuk Lymphoma 52:962-71. 2011..The collective goal is to further refine current stratification strategies to allow for an individualized, risk-adapted treatment approach that minimizes long-term late effects without compromising high cure rates...
- A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402Thomas E Witzig
Mayo Clinic, Rochester, MN, USA
Br J Haematol 170:679-86. 2015..Eighty-nine percent of patients achieved functional CR without the requirement of IFRT. This regimen is worthy of further study for early stage DLBCL in a phase III trial. ..
- The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphomaLauren S Maeda
Department of Medicine Oncology, Stanford University School of Medicine, Stanford, California, USA
Curr Opin Oncol 21:397-400. 2009..The reliable expression of CD20 has led to the evaluation of the chimeric monoclonal anti-CD20 antibody rituximab in several recent trials...
- Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancerTimothy Kuo
Oncology Division, Department of Medicine, Stanford University School of Medicine, 269 Campus Dr, CCSR 1105, Stanford, CA 94305 5151, USA
J Clin Oncol 23:5613-9. 2005..To investigate the gefitinib, fluorouracil (FU), leucovorin, and oxaliplatin regimen (IFOX) in previously treated patients with metastatic colorectal cancer...
- Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategiesAsh A Alizadeh
Division of Hematology and Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
Clin Adv Hematol Oncol 6:899-909. 2008..Finally, we discuss recent clinical trials and novel treatment approaches in the management of patients with AITL...
- Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironmentAsh A Alizadeh
Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA
Blood 118:1350-8. 2011..We conclude that the measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9) powerfully predicts overall survival in patients with DLBCL...
- Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 studySandra J Horning
Department of Medicine, Stanford University, CA, USA
Blood 115:775-7; quiz 918. 2010..This trial was registered at www.clinicaltrials.gov as #NCT00274924 [corrected]...
- Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcomeDenise K Woo
Department of Dermatology, Stanford University, Stanford, CA 94305, USA
Arch Dermatol 145:667-74. 2009....
- Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)Peter L Greenberg
Hematology Division, Stanford University Medical Center, 703 Welch Rd, Suite G 1, Stanford, CA 94305, USA
J Clin Oncol 22:1078-86. 2004....
- Non-Hodgkin lymphoma of the breastKristen Ganjoo
Department of Medical Oncology, Stanford University, Stanford, California, USA
Cancer 110:25-30. 2007..A retrospective study was done to evaluate the institutional experience in this patient population...
- Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistryNancy L Bartlett
a Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine, St Louis, MO, USA
Leuk Lymphoma . 2016..A minimum CD30 expression threshold appears to be required for antitumor activity in DLBCL; however, other factors also likely contribute to activity. (NCT01421667)...
- Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT)Lynne I Wagner
Lynne I Wagner and David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL Fengmin Zhao, Fangxin Hong, Dana Farber Cancer Institute, Boston, MA Michael E Williams, University of Virginia, Charlottesville, VA John C Krauss, University of Michigan, Ann Arbor, MI Ranjana H Advani, Stanford University, Stanford Sandra J Horning, Genentech, South San Francisco, CA Ronald S Go, Gunderson Health System, La Crosse Brad S Kahl, University of Wisconsin, Madison, WI Thomas M Habermann, Mayo Clinic, Rochester Joseph W Leach, Metro Minnesota Community Clinical Oncology Program, Minneapolis, MN Brian O Connor, Frederick Memorial Health System, Frederick, MD Stephen J Schuster, University of Pennsylvania, Philadelphia, PA and Randy D Gascoyne, British Columbia Cancer Agency, Vancouver, BC, Canada
J Clin Oncol 33:740-8. 2015..A secondary objective was to examine whether the superiority of MR versus RR on anxiety depended on illness-related coping style...
- Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomasAmin Aalipour
Stanford University Medical Center, Stanford, CA, USA
Br J Haematol 163:436-43. 2013..Recent clinical data suggest significant activity of ibrutinib as a first in class oral inhibitor of BTK. This review provides an overview of ongoing clinical studies of BTK inhibitors...
- In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II studyJoshua D Brody
269 Campus Dr CCSR rm 1105, Stanford, CA 94305, USA
J Clin Oncol 28:4324-32. 2010..In a preclinical lymphoma model, intratumoral injection of a Toll-like receptor 9 (TLR9) agonist induced systemic antitumor immunity and cured large, disseminated tumors...
- Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug developmentAndy I Chen
Division of Oncology, Stanford University Medical Center, Stanford, California
J Natl Compr Canc Netw 6:428-35. 2008..These efforts are ongoing and will hopefully guide new strategies to improve the historically poor outcome of PTCL...
- Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomographyEunice Y Tsai
Department of Dermatology, Stanford University School of Medicine, Stanford, Calif, USA
Arch Dermatol 142:577-84. 2006..To evaluate the usefulness of integrated positron emission tomography and computed tomography (PET/CT) in staging mycosis fungoides (MF) and Sézary syndrome and to correlate PET/CT data with histopathologic diagnosis of lymph nodes (LNs)...
- Breast Imaging in Women Previously Irradiated for Hodgkin LymphomaKathleen C Horst
Departments of Radiation Oncology Medicine Radiology, Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA
Am J Clin Oncol 39:114-9. 2016..There are limited data, however, as to the impact of breast MRI on cancer detection rates. The aim of the current study is to evaluate the use of breast MRI in survivors of HL treated and followed at a single institution...
- A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trialRanjana H Advani
Medical Oncology, Stanford Cancer Institute, Stanford, CA, USA
Br J Haematol 172:535-44. 2016..CEOP-P did not improve outcomes compared to historical data using CHOP. Defining optimal front line therapy in PTCL continues to be a challenge and an unmet need...
- Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale
Michelle A Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX Steven M Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY Andres Forero Torres, University of Alabama at Birmingham, Birmingham, AL Nancy L Bartlett, Washington University School of Medicine, St Louis, MO Ranjana H Advani, Stanford University Medical Center, Palo Alto Robert W Chen, City of Hope National Medical Center, Duarte, CA Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA Dirk Huebner, Takeda Pharmaceuticals International, Cambridge, MA Dana A Kennedy, Seattle Genetics, Bothell Andrei R Shustov, University of Washington Medical Center, Seattle, WA Andrew Davies, University of Southampton School of Medicine, Southampton Tim Illidge, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom
J Clin Oncol 32:3137-43. 2014..This phase I open-label study evaluated the safety and activity of brentuximab vedotin administered sequentially with CHOP or in combination with CHP (CHOP without vincristine) as front-line treatment in patients with CD30(+) PTCL...
- Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab eraSusan M Hiniker
Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California
Int J Radiat Oncol Biol Phys 92:99-106. 2015..We sought to evaluate the use of imaging (computed tomography [CT] and positron emission tomography [PET]-CT) scans and lactate dehydrogenase (LDH) in surveillance of patients with stage I to II DLBCL...
- Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatmentHolbrook Kohrt
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
Leuk Lymphoma 50:1773-84. 2009..International and multicenter clinical trials are needed for this rare and aggressive disease...
- A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinomaRanjana Advani
Oncology Division, Stanford University Medical Center, 269 Campus Drive, Stanford, CA 94305 5151, USA
Cancer 100:321-6. 2004..In a previous Phase I trial, the authors demonstrated the safety and some evidence of activity in ovarian carcinoma of aprinocarsen administered as a 21-day, continuous, intravenous infusion...
- Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 StatusMargaretha G M Roemer
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
Cancer Immunol Res 4:910-916. 2016..The paucity of β2M/MHC class I expression on HRS cells also prompts speculation regarding alternative mechanisms of action of PD-1 blockade in cHL. Cancer Immunol Res; 4(11); 910-6. ©2016 AACR...
- Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional ImagingDavid J Iberri
Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, CA, USA
Curr Treat Options Oncol 16:45. 2015..However, for selected patients with favorable characteristics, emerging data suggest that a chemotherapy-alone approach is reasonable...
- Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expressionEric D Jacobsen
Dana Farber Cancer Institute, Boston, MA
Blood 125:1394-402. 2015..Overall, significant activity with brentuximab vedotin was observed in relapsed/refractory DLBCL, and responses occurred across a range of CD30 expression. This study was registered at www.clinicaltrials.gov as #NCT01421667. ..
- Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell linesAshley A Powell
Department of Surgery, Stanford University School of Medicine, Stanford, California, USA
PLoS ONE 7:e33788. 2012..Here we demonstrate feasibility of performing high dimensional single CTC profiling, providing early insight into CTC heterogeneity and allowing comparisons to breast cancer cell lines widely used for drug discovery...
- Targeting CD40 in Waldenström's macroglobulinemiaMark Lee
Oncology Division, Stanford University Medical Center, Stanford, CA 94305, USA
Clin Lymphoma Myeloma 9:87-9. 2009..These observations support the testing of CD40-targeted agents in WM...
- Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximabAnjali V Morales
Multidisciplinary Cutaneous Lymphoma Program, Stanford Comprehensive Cancer Center, Stanford, California 94305, USA
J Am Acad Dermatol 59:953-7. 2008..Rituximab is a chimeric monoclonal IgG1 antibody directed against the CD20 antigen of B cells. Clinical efficacy of systemic rituximab in CBCL has yet to be established...
- Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignanciesRanjana Advani
Oncology Division, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
Clin Cancer Res 9:5187-94. 2003..The purpose of this study was to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and preliminary activity of BMS-188797 administered weekly...
- Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's diseaseHolbrook Kohrt
Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA
Oncol Res 18:287-92. 2009..Our observation challenges prior belief that patients with HD remain immunodeficient following therapy and argues that the clinical significance of the EBV-specific immune response in EBV-negative HD should be further investigated...
- Treatment of mantle cell lymphoma: current approach and future directionsJoshua Brody
Department of Medicine, Division of Oncology, Stanford University Medical Center, Clinical Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Crit Rev Oncol Hematol 58:257-65. 2006....
- Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiologyAnu G Jayaraman
Department of Pathology, Stanford University Medical Center, Stanford, California 94305 5324, USA
J Cutan Pathol 33:6-11. 2006....
- Splenic diffuse large B-cell lymphoma in a patient with type 1 Gaucher disease: Diagnostic and therapeutic challengesJoshua D Brody
Ann Hematol 85:817-20. 2006
- Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248Steven P Treon
Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Clin Cancer Res 13:3320-5. 2007..Waldenstrom's macroglobulinemia (WM) is a B-cell disorder. Despite advances in the therapy, WM remains incurable. As such, novel therapeutic agents are needed for the treatment of WM...